5-(3-amino-propyl)-furan-2-carboxylic acid methyl ester | 116033-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-(3-amino-propyl)-furan-2-carboxylic acid methyl ester
• 英文别名: 5-(3-Amino-propyl)-furan-2-carbonsaeure-methylester；Methyl 5-(3-aminopropyl)furan-2-carboxylate
• CAS: 116033-58-0
• 化学式: C₉H₁₃NO₃
• 分子量: 183.207
• InChiKey: AZTZIGIZTSQZSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(ξ-2-cyano-vinyl)-furan-2-carboxylic acid methyl ester 在 甲醇 、 钴 作用下， 120.0 ℃ 、14.71 MPa 条件下， 生成 5-(3-amino-propyl)-furan-2-carboxylic acid methyl ester
  参考文献：
  名称：

  DE950915

  摘要：

  公开号：

文献信息

• Methods of treatment using an EP2 selective receptor agonist
  申请人：Constan A. Alexander

  公开号：US20050203086A1

  公开（公告）日：2005-09-15

  The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP 2 selective receptor agonist.

  本发明涉及使用EP2选择性受体激动剂治疗肺动脉高压、促进关节融合、促进肌腱和韧带修复、减少继发性骨折的发生、治疗缺血性坏死、促进软骨修复、促进肢体移植后的骨愈合、促进肝脏再生、促进伤口愈合、减少胃溃疡的发生、治疗高血压、促进牙齿珐琅质或手指甲和脚趾甲的生长、治疗青光眼、治疗眼高压以及修复由转移性骨疾病引起的损伤的方法。
• Prevention of loss and restoration of bone mass by certain prostaglandin agonists
  申请人：——

  公开号：US20020016368A1

  公开（公告）日：2002-02-07

  Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  前列腺素激动剂，使用这种前列腺素激动剂的方法，包含这种前列腺素激动剂的制药组合物和包含这种前列腺素激动剂的套装。这些前列腺素激动剂对于治疗骨疾病，包括骨质疏松症，非常有用。
• Prostaglandin agonists
  申请人：——

  公开号：US20030078261A1

  公开（公告）日：2003-04-24

  This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  本发明涉及前列腺素激动剂，使用这种前列腺素激动剂的方法，含有这种前列腺素激动剂的制药组合物以及含有这种前列腺素激动剂的试剂盒。这些前列腺素激动剂对治疗骨疾病，包括骨质疏松症，是有用的。
• Osteoporosis compounds
  申请人：——

  公开号：US20020165255A1

  公开（公告）日：2002-11-07

  This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  本发明涉及前列腺素激动剂，使用这种前列腺素激动剂的方法，含有这种前列腺素激动剂的药物组合物和含有这种前列腺素激动剂的工具包。这些前列腺素激动剂可用于治疗包括骨质疏松症在内的骨疾病。
• Compounds for the treatment of osteoporosis
  申请人：PFIZER INC.

  公开号：EP0911321A2

  公开（公告）日：1999-04-28

  This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  本发明涉及前列腺素激动剂、使用这种前列腺素激动剂的方法、含有这种前列腺素激动剂的药物组合物和含有这种前列腺素激动剂的试剂盒。前列腺素激动剂可用于治疗骨质紊乱，包括骨质疏松症。